Initial Outcomes of Robotic Lower Extremity Exoskeleton Use by a Non-ambulatory Child With CP
Condition: Cerebral Palsy
MeSH terms: Cerebral Palsy
Study type: Observational

Summary: 
      There are very few evidence-based interventions for children with cerebral palsy who cannot
      walk. The Trexo-Home is a device that is newly available for rent by families, but its impact
      is unknown. By tracking and recording various outcome measures throughout this project, the
      investigators hope to inform future larger scale controlled studies.
    

Detailed description: 
      Design: This is a prospective case study to understand how a walking-aid device (Trexo-Home)
      that has been rented by a family, may impact a child with cerebral palsy (CP) who cannot
      walk. The decision to use the device was separate from this research, and the decision to do
      research on it's use was secondary, making it an observational study. The proposed procedures
      below may be modified to adapt to the child and family's interest and needs.

      Background and Rationale: Evidence suggests that positive health outcomes are associated with
      reducing sedentary behaviour and sitting time. For individuals with significant motor
      impairments, spending the majority of their days sitting in a wheelchair is often a reality,
      potentially leading to secondary preventable chronic diseases such as type 2 diabetes,
      cardiovascular disease, and some cancers. Many children with CP have mobility limitations,
      and approximately 30% are non-ambulatory or require assistive devices. Currently, there are
      very few treatments available for non-ambulatory children with CP, and treatments may be
      invasive or have undesirable side effects. Tréxō Robotics (Trexo) aims to bridge the gap in
      treatments available for non-ambulatory children. Trexo offers a robotic exoskeleton that
      enables children to walk using a gait trainer with an external power source with the safety
      of a walker. This revolutionary technology is new to the world of pediatric rehabilitation,
      and Trexo Home provides the advantage of versatility to use the device at home or in the
      community on a daily basis. This means children who would otherwise spend most of their day
      sitting in a wheelchair can now stand and walk on a daily basis using this device in a
      familiar setting. Presently, the impacts of its use are unknown, however similar exoskeletons
      used with adults with spinal cord injury (SCI) show promising health benefits beyond
      enjoyment of walking again, such as improvements in spasticity and regularity of bowel
      movements.

      This case study will involve one 7 year old child with CP who is functionally non-ambulatory.
      This child's family holds an agreement to lease the Trexo Home for a period of 6 months.
      Through the exploratory nature and prospective design of this case study, the investigators
      will gather critical data for informing future larger scale, controlled studies. With limited
      pediatric data related to the use of robotic assisted movement, this information could
      potentially add to or alter current interventions recommended for children with significant
      motor impairments.

      Objective: The objective of this case study is to thoroughly assess the impact of Trexo Home
      use in one 7 year old child with CP (Gross Motor Function Classification System level IV).

      i) Does using a robotic exoskeleton meet the family's primary goal - facilitating their
      child's experience of joy? ii) What is the family's experience around feasibility and the
      child's tolerability of using the Trexo at home or in the community? iii) What are the
      initial physiologic outcomes following twelve weeks of Trexo use?

      Methods: Implementation of this project will occur over 16 weeks, with a baseline period of 4
      weeks , an intervention period of 12 weeks. Throughout the project the investigators will
      have weekly contact with the participant's family. This frequency was selected in discussion
      with the family.

      Joy will be evaluated using a Smiley Face Likert Scale, completed separately by the child and
      the parents on a weekly basis.

      Feasibility and Tolerability will be quantified by number of minutes of Trexo Home use and
      number of steps taken per day. Reasons for skipping or abbreviating a therapeutic session
      will be recorded.

      Physiologic outcomes evaluate key symptoms of cerebral palsy and secondary complications.

      Spasticity will be assessed every second week using clinical measures (modified Tardieu and
      modified Ashworth Scale) and quantitative measures (the Portable Spasticity Assessment Device
      which differentiates reflexive and intrinsic stiffness).

      Range of motion (ROM) at the hip and knee joint bilaterally will be measured via standardized
      goniometry, and will be done every second week, on alternate weeks from the spasticity
      assessment.

      The child's sitting balance will be assessed monthly using the Early Clinical Assessment of
      Balance Version 2.

      Bowel movement frequency and any related medication use will be tracked with daily diaries.
      This area has significant potential to enhance the quality of life of an individual, and
      adults with a spinal cord injury using exoskeleton have noted benefits.

      Videos of the balance assessment and of free movement will occur in phase 1 and every month
      during phase 2, the intervention period. Video of the child using the Trexo device will be
      taken every two weeks in phase 2.
    

Intervention name(s): trexo Home
Intervention type(s): Device
Intervention description(s): 12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        GMFCS IV
      
Keywords: exoskeleton device